Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionEllerson Group Inc /adv
Latest Disclosed Ownership8,079 shares
Latest Disclosed Value $ 6,242,159
Ellerson Group Inc /adv reports 0.55% increase in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On May 4, 2026 - Ellerson Group Inc /adv filed a 13F-HR form disclosing ownership of 8,079 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $6,242,159 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 9, 2026 disclosing 8,035 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of 0.55% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-04 2026-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 8,079 44 0.55 6,242 0.66 4.0909
2026-02-09 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 8,035 -67 -0.83 6,202 36.14 4.1961
2025-11-10 2025-09-30 13F REGENERON PHARMACEUTICALS OM 75886F107 8,102 2,671 49.18 4,556 59.77 2.8341
2025-08-07 2025-06-30 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 5,431 -2,711 -33.30 2,851 -44.78 2.0101
2025-08-07 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 8,142 5,164
2025-05-12 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 8,142 1,222 17.66 5,164 4.75 4.1054
2025-02-07 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 6,920 59 0.86 4,929 -31.66 3.5971
2024-11-12 2024-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 6,861 -127 -1.82 7,213 -1.80 5.6634
2024-08-07 2024-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 6,988 -84 -1.19 7,345 7.90 5.5880
2024-05-08 2024-03-31 13F SHELL COM 75886F107 7,072 -23 -0.32 6,807 9.23 5.2033
2024-02-06 2023-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 7,095 0 0.00 6,231 6.73 5.4052
2023-11-14 2023-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 7,095 -134 -1.85 5,839 12.40 5.4403
2023-08-10 2023-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 7,229 170 2.41 5,194 -10.45 4.9469
2023-05-05 2023-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 7,059 -4 -0.06 5,800 13.81 6.2860
2023-02-09 2022-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 7,063 7,063 5,096 5.3972
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.